Dantonio Paul, Klug Tracy, Yazdanpanah Golriz, Haynes Christopher, Zhou Hui, Hopkins Patrick, Vogt Robert, Lee Rachel, Cuthbert Carla, Petritis Konstantinos
Newborn Screening and Molecular Biology Branch, Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, GA 30341, USA.
Missouri State Public Health Laboratory, Newborn Screening Unit, 101 N. Chestnut Street, Jefferson City, MO 65101, USA.
Int J Neonatal Screen. 2025 Jun 10;11(2):44. doi: 10.3390/ijns11020044.
Newborn bloodspot screening for one or more lysosomal storage disorders (NBS-LSD) is currently performed by many public health NBS laboratories globally. The screening tests measure activities of selected lysosomal enzymes on dried blood spot (DBS) specimens collected from newborns by the heel stick method Because these assays measure enzyme activity, the quantitative results are dependent on the particular analytical method. DBS quality control (DBS QC) materials with assay-specific certified values that span the relevant range from typical to LSD-affected newborns are an important component of quality assurance in NBS laboratories. The Newborn Screening Quality Assurance Program (NSQAP) at the U.S. Centers for Disease Control and Prevention (CDC) provides public health NBS laboratories with DBS QC sets for NBS-LSD comprising four admixtures of pooled umbilical cord blood and a base pool made from leukodepleted peripheral blood and heat-inactivated serum. To evaluate the suitability of these materials for use with digital microfluidics fluorometry (DMF) assays which can currently measure the activity of four enzymes (acid α-galactosidase (GLA); acid β-glucocerebrosidase (GBA); acid α-glucosidase (GAA); and iduronidase (IDUA)), CDC collaborated with the Newborn Screening Unit at the Missouri State Public Health Laboratory (MSPHL). Using MSPHL criteria, we found that the certified results from each of two DBS QC lots collectively spanned the range from typical (screen negative) to enzyme deficient (screen positive) newborn DBS levels for each of the four lysosomal enzymes measured. The range included borderline results that would require repeat screening of the newborn under the MSPHL protocol. We conclude that these DBS QC preparations are suitable for use as external quality control materials for DMF assays used to detect LSDs in newborns.
目前,全球许多公共卫生新生儿筛查实验室都在开展针对一种或多种溶酶体贮积症的新生儿干血斑筛查(NBS-LSD)。筛查测试通过足跟采血法从新生儿采集的干血斑(DBS)标本上测量选定溶酶体酶的活性。由于这些检测方法测量的是酶活性,因此定量结果取决于特定的分析方法。具有特定检测方法认证值且涵盖从典型新生儿到受溶酶体贮积症影响新生儿相关范围的DBS质量控制(DBS QC)材料,是新生儿筛查实验室质量保证的重要组成部分。美国疾病控制与预防中心(CDC)的新生儿筛查质量保证项目(NSQAP)为公共卫生新生儿筛查实验室提供用于NBS-LSD的DBS QC套件,该套件包含四种脐血混合样本以及一种由去白细胞外周血和热灭活血清制成的基础样本。为了评估这些材料是否适用于目前可测量四种酶(酸性α-半乳糖苷酶(GLA)、酸性β-葡萄糖脑苷脂酶(GBA)、酸性α-葡萄糖苷酶(GAA)和艾杜糖醛酸酶(IDUA))活性的数字微流控荧光测定(DMF)检测,CDC与密苏里州公共卫生实验室(MSPHL)的新生儿筛查部门进行了合作。根据MSPHL的标准,我们发现两个DBS QC批次中每一批的认证结果共同涵盖了所测量的四种溶酶体酶从典型(筛查阴性)到酶缺乏(筛查阳性)新生儿DBS水平的范围。该范围包括根据MSPHL方案需要对新生儿进行重复筛查的临界结果。我们得出结论,这些DBS QC制剂适合用作DMF检测的外部质量控制材料,用于检测新生儿中的溶酶体贮积症。